Cargando…

Remdesivir does not increase risk of AKI or ALI in COVID-19 patients

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990619/ http://dx.doi.org/10.1007/s40278-022-12689-0

Ejemplares similares

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

Health Canada: AKI or ARF with remdesivir for COVID-19?
Publicado: (2021)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Hypophosphatemia is an independent risk factor for AKI among hospitalized patients with COVID-19 infection
por: Chen, Zijin, et al.
Publicado: (2021)

Trajectory of AKI and hospital mortality among patients with COVID-19
por: Kim, Seong Geun, et al.
Publicado: (2023)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Quality of ADR reporting evaluated for remdesivir trials of COVID-19
Publicado: (2020)

Remdesivir vs tocilizumab in COVID-19: adverse event profiles
Publicado: (2021)

The effects of timing onset and progression of AKI on the clinical outcomes in AKI patients with sepsis: a prospective multicenter cohort study
por: Wang, Meiping, et al.
Publicado: (2023)

Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021)

Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021)

Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients
por: Wang, Yujia, et al.
Publicado: (2020)

Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021)

NSAID use does not increase risk of COVID-19-related death
Publicado: (2021)

Remdesivir use in severe renal impairment: benefits outweigh risks
Publicado: (2021)

Dialysis Complications in AKI Patients Treated with Extended Daily Dialysis: Is the Duration of Therapy Important?
por: Ballarin Albino, Bianca, et al.
Publicado: (2014)

Performance of the renal resistive index and usual clinical indicators in predicting persistent AKI
por: Fu, You, et al.
Publicado: (2022)

Development of a Risk Score for AKI onset in COVID-19 Patients: COV-AKI Score
por: Palomba, Henrique, et al.
Publicado: (2023)

Depletion of macrophages with clodronate liposomes partially attenuates renal fibrosis on AKI–CKD transition
por: Hu, Zhizhi, et al.
Publicado: (2023)

Fluid accumulation increases the risk of AKI progression and death in critically ill patients with early AKI
por: Raimundo, MR, et al.
Publicado: (2014)

Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
por: Hegazy, Sahar Kmal, et al.
Publicado: (2023)

Association between triglyceride-glucose index and AKI in ICU patients based on MIMICIV database: a cross-sectional study
por: Jin, Zihan, et al.
Publicado: (2023)

Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease
por: Selvaraj, Vijairam, et al.
Publicado: (2022)

Proton pump inhibitors increase risk of COVID-19
Publicado: (2020)

Chloroquine and hydroxychloroquine increase risk of death in COVID-19
Publicado: (2020)

Significance of platelets in the early warning of new-onset AKI in the ICU by using supervise learning: a retrospective analysis
por: Pan, Pan, et al.
Publicado: (2023)

HYAL1 deficiency attenuates lipopolysaccharide-triggered renal injury and endothelial glycocalyx breakdown in septic AKI in mice
por: Xing, Hongxia, et al.
Publicado: (2023)

Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
por: Darawshi, Said, et al.
Publicado: (2020)

A Patient Presenting with AKI, Proteinuria, and Anasarca
por: Rosenstiel, Paul, et al.
Publicado: (2023)

No increased risk for venous thromboembolism after COVID-19 vaccination
Publicado: (2022)

NSAIDs do not increase risk or severity of COVID-19 infections
Publicado: (2021)

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19
por: Buxeda, Anna, et al.
Publicado: (2021)

Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance
por: Aiswarya, Dhanapalan, et al.
Publicado: (2020)

REMDESIVIR-INDUCED EXTREME SINUS BRADYCARDIA IN COVID-19
por: Hamilton, Steven A., et al.
Publicado: (2022)

Remdesivir for patients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2021)

Utilizing reclassification to explore characteristics and prognosis of KDIGO(SCr) AKI subgroups: a retrospective analysis of a multicenter prospective cohort study
por: Dong, Gui-Ying, et al.
Publicado: (2021)

540. Does Remdesivir Impact the Clinical Outcome of Patients with COVID 19 Infection?
por: Gunasekaran, Karthik, et al.
Publicado: (2021)

Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19
por: Finn, Arkadiy, et al.
Publicado: (2022)

AKI in Patient with Acute Viral Hepatitis
por: Ramteke, Vishal, et al.
Publicado: (2023)

Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0h2i1i839a8f7ds2kgo2qde00u